Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Recs

0
Player Avatar pchop123 (76.55) Submitted: 10/3/2012 3:43:49 PM : Underperform Start Price: $9.45 SNTA Score: +5.83

poor development record by management will liiely lead to a very weak pipeline

Featured Broker Partners


Advertisement